Protection against Parkinson's disease progression: clinical experience.

  • LeWitt P
  • Taylor D
  • 11


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Treatments with potential neuroprotective capability for Parkinson's disease (PD) have been investigated in randomized, controlled, clinical trials and other studies since the mid-1980s. Although promising leads have arisen, no therapy has been proven to halt or slow disease progression. Several large-scale studies have highlighted progress in methodology, as well as the frustrations of translating laboratory science to practical applications. This review summarizes findings from clinical trials with several classes of compounds, including monoamine oxidase-B inhibitors (selegiline, lazabemide, rasagiline), dopaminergic drugs (ropinirole, pramipexole, levodopa), antioxidant strategies (alpha-tocopherol), mitochondrial energy enhancers (coenzyme Q(10), creatine), antiapoptotic agents (TCH346, minocycline, CEP-1347), and antiglutamatergic compounds (riluzole). Beyond small-molecule pharmacology, gene therapy approaches, such as delivering neurotrophic substances (e.g., neurturin) by viral vector, are the next generation of treatment options.

Author-supplied keywords

  • Animals
  • Antioxidants
  • Antioxidants: therapeutic use
  • Clinical Trials as Topic
  • Clinical Trials as Topic: methods
  • Disease Progression
  • Dopamine Agonists
  • Dopamine Agonists: therapeutic use
  • Humans
  • Monoamine Oxidase Inhibitors
  • Monoamine Oxidase Inhibitors: therapeutic use
  • Parkinson Disease
  • Parkinson Disease: pathology
  • Parkinson Disease: prevention & control

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Peter a LeWitt

  • Danette C Taylor

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free